Skip to main content

Scilex Holding Co

SCLX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001820190

No open-market purchases or sales by Scilex Holding Co insiders were filed in the last 90 days; 73 institutions reported holding it in 13F filings for Q2 2026, worth $5.48M in total; no superinvestor holds it.

Other share classesSCLXW

Q3 2023 vs. Q2 2023

How the institutions holding Scilex Holding Co changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of SCLX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders9381−12
Shares21.5M29.1M+7.55M (+35.1%)
Value$119.8M$40.7M−$79.1M (−66.0%)

New holders (9)

Institutions that held Scilex Holding Co at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to SCLX in Q3 2023
InstitutionSharesValue% of portfolio
Hudson Bay Capital Management LP474,683$664.6K0.01%
Apollon Wealth Management, LLC50,000$70.0K0.00%
Bank of New York Mellon Corp48,459$67.8K0.00%
Alliancebernstein L.P.38,956$54.5K0.00%
Collective Family Office LLC16,300$22.8K0.01%
Renaissance Technologies LLC13,521$19.0K0.00%
SG Americas Securities, LLC11,301$16.0K0.00%
Pacifica Partners Inc.493$7300.00%
SOA Wealth Advisors, LLC.204$2860.00%

Sold out (21)

Institutions that held Scilex Holding Co at the end of Q2 2023 and filed for Q3 2023 without it.